Mutations in the thyroid hormone (TH) transporter monocarboxylate transporter 8 (MCT8) result in severe intellectual and motor disability. At present, no effective therapy is available to restore TH signaling in MCT8-dependent tissues. Recent in vitro studies in stable overexpression cell models suggested that the function of certain mutant MCT8 proteins, specifically those that affect protein stability and intracellular trafficking (e.g., p.F501del), could be partially recovered by chemical chaperones. However, the effects of chaperones have not been demonstrated in other commonly used models for MCT8 deficiency, including transient overexpression models and patient-derived fibroblasts. Here, we demonstrate that the chemical chaperone 4-phenylbutyric acid (PBA) similarly potentiates the T3 transport function of wild-type and p.F501del mutant MCT8 in transiently transfected COS-1 cells by increasing MCT8 messenger RNA, total protein, and cell surface expression levels. Although PBA also increased the cell surface expression levels of the p.R445L mutant, no functional improvement was observed, which is in line with the proposed important role of Arg445 in substrate translocation. In contrast, PBA showed only minimal effects in ex vivo studies using control or p.F501del patient-derived fibroblasts. Moreover, the MCT8-specific inhibitor silychristin did not change these minimal effects, suggesting that the underlying mechanism is unrelated to the rescue of functional MCT8. Together, these findings indicate that the potency of chaperones to rescue mutant MCT8 function strongly depends on the cellular model and stress the need for further preclinical studies before clinically available chaperones should be considered as a treatment option in patients with MCT8 deficiency. (Endocrinology 159: 1290(Endocrinology 159: -1302(Endocrinology 159: , 2018 M onocarboxylate transporter 8 (MCT8; SLC16A2) facilitates the transport of thyroid hormone (TH) across the cell membrane and is crucial for TH transport across the blood-brain barrier (BBB) and into neuronal cells (1, 2). Given the important role of TH during brain development, functional MCT8 is vital for normal neurocognitive development. Mutations in MCT8 result in the Allan-Herndon-Dudley syndrome (or MCT8 deficiency), characterized by severe intellectual and motor disability and abnormal serum thyroid function tests comprising a high T3, low T4 and rT3, and high-normal to high thyroid-stimulating hormone (3, 4). (5)]. Different pathogenic mechanisms may underlie MCT8 inactivation, e.g., deletions or nonsense mutations that prevent the production of fulllength MCT8 protein or missense mutations that specifically interfere with substrate translocation (e.g., p.R445C or p.D498N) or with protein expression and subcellular localization (e.g., p.G564R and p.G282C) (6-8). Although most mutations result in (near-) complete inactivation of MCT8 transport function, some mutant proteins retain considerable residual transport function. Different in vitro models are used to determine the impact of mutations on MCT8 function, including transient and Abbreviations: BBB, blood-brain barrier; cDNA, complementary DNA; CRYM, m-crystallin; DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MCT8, monocarboxylate transporter 8; mRNA, messenger RNA; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NaPB, sodium phenylbutyrate; PBA, 4-phenylbutyric acid; SEM, standard error of the mean; TH, thyroid hormone; WT, wild-type.
M onocarboxylate transporter 8 (MCT8; SLC16A2) facilitates the transport of thyroid hormone (TH) across the cell membrane and is crucial for TH transport across the blood-brain barrier (BBB) and into neuronal cells (1, 2) . Given the important role of TH during brain development, functional MCT8 is vital for normal neurocognitive development. Mutations in MCT8 result in the Allan-Herndon-Dudley syndrome (or MCT8 deficiency), characterized by severe intellectual and motor disability and abnormal serum thyroid function tests comprising a high T3, low T4 and rT3, and high-normal to high thyroid-stimulating hormone (3, 4) .
Many different mutations in MCT8 have been identified [reviewed in (5) ]. Different pathogenic mechanisms may underlie MCT8 inactivation, e.g., deletions or nonsense mutations that prevent the production of fulllength MCT8 protein or missense mutations that specifically interfere with substrate translocation (e.g., p.R445C or p.D498N) or with protein expression and subcellular localization (e.g., p.G564R and p.G282C) (6) (7) (8) . Although most mutations result in (near-) complete inactivation of MCT8 transport function, some mutant proteins retain considerable residual transport function. Different in vitro models are used to determine the impact of mutations on MCT8 function, including transient and stable overexpression systems and patient-derived fibroblasts. Patient-derived fibroblasts especially allow the study of mutations in MCT8 under endogenous conditions and generally show a good correlation with the severity of clinical disease (9, 10) . Recently, induced pluripotent stem cells derived from MCT8-deficient patients have been successfully differentiated toward different cell lineages, providing unique opportunities for ex vivo analyses of MCT8 deficiency (11) .
Currently, there is no established therapy for MCT8 deficiency, although preclinical studies on TH analog therapy have shown promising results (12) . Another therapeutic approach that has been recently explored in vitro is the use of chemical and pharmacological chaperones (13, 14) . Being key players in the protein quality control system, endogenous chaperones govern the correct folding of proteins and their assembly in complexes, thereby preventing their degradation and aggregation. This ensures proper subcellular trafficking and protein function [reviewed in (15, 16) ]. Exogenous administration of chaperones has been explored as therapeutic approach in neurodegenerative disorders that involve protein folding defects, such as Alzheimer's disease, Parkinson disease, and Huntington disease [reviewed in (15, 16) ]. In addition, chaperones have been shown to rescue misfolded mutant transporter proteins, including different members of the ABC transporter family such as cystic fibrosis transmembrane conductance regulator [reviewed in (17) ]. In the latter, different chemical chaperones were found to enhance the translocation of the most commonly encountered p.F508del mutant to the cell membrane and potentiate its function (17) . Likewise, the chemical chaperones 4-phenylbutyric acid (PBA), its salt sodium phenylbutyrate (NaPB), and dimethyl sulfoxide (DMSO) were recently shown to stabilize and potentiate the cell membrane expression of the p.F501del mutant MCT8 protein in stably transfected MadinDarby canine kidney cells, thereby increasing its TH transport capacity (13) . Several other MCT8 mutants were recently reported that could also be potentially rescued upon chaperone treatment (14) . Interestingly, these mutations have all been associated with milder forms in the clinical spectrum of MCT8 deficiency and retain at least some residual transporter activity in experimental studies (9, (18) (19) (20) . Importantly, previous studies in transiently transfected cells could not demonstrate such beneficial effects (21) . The therapeutic potency of chaperones has not been evaluated in patientderived fibroblasts so far.
For these reasons, we here explored the therapeutic potential of chaperones in transiently transfected COS-1 cells and patient-derived fibroblasts, which are established and frequently used cellular models for MCT8 deficiency. Chaperone treatment modestly potentiated p.F501del mutant MCT8 function in transiently transfected COS-1 cells. However, chaperones showed minimal effects in patient-derived fibroblasts, unrelated to the rescue of MCT8 function. These findings indicate that the potency of chaperones to rescue mutant MCT8 function strongly depends on the cellular model. Further preclinical studies are warranted before clinically available chaperones should be considered as a treatment option in patients with MCT8 deficiency.
Experimental Procedures
Materials X-tremeGENE9 transfection reagent was obtained from Roche Diagnostics (Woerden, Netherlands). DMSO, PBA, NaPB, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (Zwijndrecht, Netherlands). Nonradioactive iodothyronines were obtained from Henning (Berlin, Germany). I)T 4 were prepared as previously described (22) . All cell culture flasks and plates were obtained from Corning (Schiphol, Netherlands).
Plasmids
Cloning of wild-type (WT) human MCT8 in pcDNA3 and of human m-crystallin (CRYM) in pSG5 has been previously described (23, 24) , as well as the generation of the p.F501del mutant MCT8 construct (9) . CRYM is a cytosolic TH-binding protein, which greatly reduces TH efflux and thereby increases the net cellular TH accumulation. The p.R445L and p. Q97fsX mutations were introduced into the WT MCT8 complementary DNA (cDNA) construct as described previously (25) , using primers listed in Supplemental Table 1 . DNA sequencing was performed to confirm the presence of the introduced mutations. Positions of the mutations are determined using the NM_006517.3 reference sequence, which uses +1 as the A of the ATG translation initiation codon of the long MCT8 translational isoform, with the initiation codon as codon 1.
Cell culture, transfection, and chaperone treatment in transient expression models COS-1 and JEG-3 cells were cultured in DMEM/F-12 medium (Life Technologies, Bleiswijk, Netherlands) supplemented with 9% heat-inactivated fetal calf serum (Invitrogen, Breda, Netherlands) and 2% penicillin/streptomycin (Roche Diagnostics). For T3 uptake assays, COS-1 or JEG-3 cells were cultured in 24-well plates (uptake assays), 6-well plates (immunoblotting), or 10-cm dishes (surface biotinylation assays) and transiently transfected at 70% confluence with the indicated concentrations of WT or mutant MCT8. Standard conversion factors were used to convert plasmid concentrations between different well formats and confirmed by analysis of plasmid dose-dependent T3 uptake in 24-and 6-well plates. For uptake assays, cells were cotransfected with 100 ng (24-well format) or 250 ng (6-well format) CRYM. We have previously demonstrated the absence of differences in transfection efficiency between WT and mutant MCT8 constructs (26) . In case of chaperone treatment, incubation medium was substituted 1 day after transfection by incubation medium containing the indicated concentrations of DMSO, PBA, or NaPB. Next, cells were cultured for 48 hours in the presence or absence of chaperones with refreshment of medium after 24 hours, in line with previously reported studies (13, 14) .
Cell culture and chaperone treatment of human fibroblasts Human fibroblasts were derived from skin biopsies and were cultured in six-well plates (for uptake assays and RNA isolation) or 10-cm dishes (for immunoblotting) in DMEM/F-12 medium (Life Technologies) supplemented with 9% heat-inactivated fetal calf serum (Invitrogen) and 2% penicillin/streptomycin (Roche Diagnostics). Chaperone treatment was initiated at indicated concentrations of DMSO, PBA, or NaPB at 90% confluence for indicated time frames, and medium was refreshed daily.
Toxicity assays
Toxicity was assessed by determination of total protein levels using a Bradford assay according to manufacturer's protocol (Bio-Rad, Veenendaal, Netherlands) and cell viability using an MTT (Sigma-Aldrich) assay in cells exposed to indicated chaperone concentrations for 48 hours as described previously. Assays were performed in parallel to the T3 transport studies. Measurement of total protein levels was carried out in cells cultured in 24-well plates similarly transfected as for T3 uptake assays. MTT assays were carried out as previously described (25) using untransfected cells cultured on a 96-wells plate.
TH uptake studies
Cells were washed with incubation medium [Dulbecco's phosphate-buffered saline containing 0.1% bovine serum albumin (Sigma-Aldrich) and 0.1% glucose] and incubated for 30 minutes at 37°C in incubation medium containing 1 nM unlabeled T3 (Sigma-Aldrich) and 50,000 cpm ( 125 I)T3. After incubation, cells were briefly washed with incubation medium and lysed in 0.1 M NaOH. The amount of internalized radioactivity was measured with a g-counter.
Surface biotinylation assays
Cell surface biotinylation assays were performed as previously described (25) . Briefly, cell surface proteins were labeled with EZ-link Sulfo-NHS-biotin (Thermo Fisher Scientific, Bleiswijk, Netherlands), and cells were subsequently lysed with immunoprecipitation buffer [50 mM tris(hydroxymethyl) aminomethane-HCl, 150 mM NaCl, 10 mM EDTA, 1% Triton X-100], containing protease inhibitor cocktail (Roche Diagnostics). An aliquot (5% of the total volume) of the clarified lysate was saved as an input control. The biotinylated cell surface proteins were isolated using Neutravidin agarose beads (Thermo Fisher Scientific) and eluted by incubating the beads for 10 minutes at 70°C with NuPAGE 13 lithium dodecyl sulfate loading buffer (Thermo Fisher Scientific) prior to immunoblot analyses as described later.
Immunoblotting
Immunoblotting was performed as previously described (25) . After incubation for 10 minutes at 70°C in presence of NuPAGE 13 lithium dodecyl sulfate loading buffer (Thermo Fisher Scientific), 15 mg of total lysate was separated on a 4% to 20% gradient Mini-PROTEAN TGX Precast Protein Gel (BioRad), blotted to polyvinylidene difluoride membranes (Thermo Fisher Scientific), blocked with 5% milk, and probed overnight at 4°C with rabbit anti-MCT8 antibody. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control. MCT8 and GAPDH were visualized as previously described (25) .
Quantitative polymerase chain reaction
Total RNA was extracted from fibroblasts and transfected COS-1 cells cultured in six-well plates using the High Pure RNA Isolation Kit (Roche Diagnostics), and cDNA was produced from 1 mg messenger RNA (mRNA) using the Transcriptor High Fidelity cDNA Synthesis Kit (Roche Diagnostics) according to the manufacturer`s protocol. Quantitative polymerase chain reaction was performed as previously described, using a probe-based assay for the detection of MCT8 and cyclophilin A (12) and the qPCR Core Kit for SYBR Green (Eurogentec, Maastricht, Netherlands) and primers listed in Supplemental Table 1 for the detection of African green monkey-specific GAPDH. Expression levels are presented as fold difference compared with untreated cells.
Statistical analysis
All uptake results are expressed as means 6 standard error of the mean (SEM) of at least three independent experiments in duplicate. Statistical significance was determined using indicated statistical tests carried out in GraphPad Prism version 6 (GraphPad, La Jolla, CA).
Ethical considerations
Skin fibroblasts were kindly provided by care-giving physicians and concerned stored samples that were previously collected for diagnostic purposes. Written informed consent was obtained from the parents or legal representatives of the involved patients and controls. This study was conducted in agreement with the Medical Research Involving Human Subjects Act and was evaluated and granted by the Medical Ethical Committee of the Erasmus Medical Center, Rotterdam, Netherlands (Medical Ethical Committee identifier: MEC-2015-362).
Results
Because the proposed mechanism of chaperone action entails the stabilization and improvement of cell membrane expression of (mutant) MCT8 protein, we postulated that the effect size of chaperone therapy depends on the production rate of (mutant) MCT8 protein in untreated cells. For this reason, we first performed a plasmid dose titration curve by transiently cotransfecting COS-1 cells with increasing amounts of WT MCT8 plasmid and a fixed amount of CRYM plasmid (100 ng) using 24-well plates. Maximum T3 uptake was observed at 25 to 100 ng WT MCT8 [ Fig. 1(a) ]. To determine the optimal amount of CRYM plasmid, we also transiently cotransfected COS-1 cells with a fixed amount of WT MCT8 plasmid (50 ng) and increasing amounts of CRYM plasmid, yielding maximum T3 uptake at $50 ng CRYM plasmid (Supplemental Fig. 1A ). To verify the standard conversion factors between different well formats, a similar dose-response curve was analyzed in a six-well plate format showing maximum induction of T3 uptake at 100 ng MCT8 plasmid (Supplemental Fig. 1B ). Parallel immunoblot analyses of lysates of COS-1 cells cultured in six-well plates revealed that MCT8 protein expression was hardly detectable using up to 100 ng (six-well format). MCT8 protein was detected as described in the legend of Fig. 1. MCT8 and GADPH expression levels were quantified by densitometry using ImageJ. WT and mutant MCT8 Figure 2 . (Continued). expression levels are expressed as MCT8/ GADPH ratio relative to WT MCT8 (100%) and presented as mean 6 SEM of three independent experiments. Statistical significance was tested using one-way analysis of variance followed by Dunnett multiple-comparison test. Statistically significant differences are indicated as follows: *P , 0.05; ***P , 0.005. AB, antibody; AU, arbitrary unit; EV, empty vector.
plasmid [ Fig. 1(b) ]. At plasmid amounts above 100 ng, a dose-dependent increase in MCT8 monomers and homodimers was observed [ Fig. 1(b) ]. Similar results were obtained in JEG-3 cells (data not shown). Together, these findings indicate plasmid dose-dependent increases in MCT8 protein expression and TH uptake, although the uptake plateaus at a relatively lower plasmid dose.
To evaluate the effect of chaperone treatment, we selected three different MCT8 mutations that have been identified in patients with MCT8 deficiency: (1) p.F501del, which has been previously reported to respond to chaperones (13), (2) p.R445L, a recently newly identified mutation that affects the presumed substrate-interacting residue Arg445 (6, 25, 27) , and (3) p.Q97fsX, which results in a frameshift and premature truncation of the protein, precluding a response to chaperone treatment. Upon transient expression in COS-1 cells, the p.F501del mutant showed considerable residual T3 uptake capacity, whereas the p.R445L and p. Q97fsX mutants were functionally inactive [ Fig. 2(a) ]. Total expression levels of the p.R445L mutant were not significantly different from WT, whereas those of the p.F501del mutant were slightly reduced [ Fig. 2(b) ]. The cell surface expression levels of both mutants were significantly reduced [ Fig. 5 (see below)]. As expected, the p.Q97fsX mutant could not be detected at the protein level due to loss of the epitope for antibody recognition. Similar results were obtained in JEG-3 cells (Supplemental Fig. 2A-2C ).
Toxicology studies in transfected and untransfected COS-1 cells revealed that the chemical chaperones PBA and NaPB strongly affected cell viability and total protein content at concentrations above 1 mM, whereas a concentration of 1% DMSO was well tolerated (Supplemental Fig. 3A-3D ). Because JEG-3 cells already showed an increased cell death at the lowest chaperone concentrations (data not shown), COS-1 cells were selected for further experiments. We next evaluated the effects of the highest tolerable concentrations of different chaperones on WT or mutant MCT8-mediated T3 uptake in COS-1 cells. For this Figure 3 . T3 uptake levels in COS-1 cells transiently transfected with either (a) 1, (b) 10, or (c) 50 ng plasmid encoding WT or indicated mutant MCT8 and 100 ng CRYM after preincubation in absence (control) or presence of indicated concentrations of DMSO, PBA, or NaPB (24-well format). All uptake values are corrected for background TH uptake levels observed in COS-1 cells transfected with pcDNA3 empty vector preincubated under the corresponding conditions. Data of WT and indicated mutants is provided as mean 6 SEM absolute T3 uptake values (left panels; n = 3). p.F501del mutant MCT8-mediated T3 uptake capacity after the different preincubation conditions is also expressed relative to WT MCT8-expressing cells treated with the corresponding chaperone (right panels). Statistical significance was tested using two-way analysis of variance followed by Bonferroni multiplecomparison test. Statistically significant differences are indicated as follows: *P , 0.05; **P , 0.01. AB, antibody; AU, arbitrary units; EV, empty vector.
purpose, COS-1 cells were transiently cotransfected with nonsaturating (1 or 10 ng) or saturating (50 ng) amounts of WT or mutant MCT8 plasmid and CRYM. Preincubation for 48 hours with 1% DMSO did not potentiate T3 uptake by WT or mutant MCT8 at any plasmid dose [ Fig. 3(a)-3(c), left panels] . In contrast, preincubation for 48 hours with 1 mM PBA significantly increased T3 uptake by both WT MCT8 and the p.F501del mutant in COS-1 cells transfected with 1 or 10 ng plasmid. The fold increase was the same for WT MCT8 and the p.F501del mutant [ Fig. 3(a) and 3(b) , left panels]. No effects were observed for the p.R445L or p.Q97fsX mutant at any plasmid dose [ Fig. 3(a) and 3(b) ]. T3 uptake by either WT MCT8 or the p.F501del mutant was not increased by chaperone treatment after transfection with 50 ng cDNA [ Fig. 3(c) ]. Please note that under these conditions a slight decrease of total protein levels was observed (Supplemental Fig. 3 ), which may indicate cellular toxicity. As expected, similar results were obtained with NaPB, which provides the same chemical composition in solution as PBA [ Fig. 3(a)-3(c) ]. Higher concentrations of PBA (10 mM), NaPB (10 mM), or DMSO (2%) decreased intracellular T3 accumulation, likely due to the reduced cellular viability, whereas no effects on T3 transport levels were observed after preincubation with lower concentrations of PBA (0.1 mM), NaPB (0.1 mM), or DMSO (0.5%) (data not shown). Together, these findings suggest that PBA does not specifically rescue the function of the p.F501del mutant, but rather potentiates T3 uptake by cells overexpressing WT MCT8 or mutants with significant residual activity.
To further elucidate the mode of action of PBA, parallel immunoblot analyses were performed that showed an increase in protein expression levels of WT MCT8 and the p.F501del and p.R445L mutants upon preincubation with 1 mM PBA, but not 1% DMSO as compared with cells cultured in control medium (Fig. 4) . A similar increase in MCT8 protein expression levels was observed using NaPB (data not shown). In addition, preincubation with 1 mM PBA increased the abundance of WT MCT8 and both p.F501del and p.R445L mutants at the cell membrane (Fig. 5) . The proportion of the total amount of WT MCT8 or the p.R445L mutant protein expressed at the cell membrane did not change (10% and Figure 4 . Representative immunoblots on total lysates derived from COS-1 cells transfected with 100 ng WT or indicated mutant MCT8 (six-well format) preincubated for 48 hours in absence or presence of indicated concentrations of PBA or DMSO. MCT8 protein was detected as described in the legend of Fig. 1 . Please note that a higher scanning intensity was used compared with Figs. 1 and 2 to obtain appropriate signal intensities. MCT8 and GADPH expression levels were quantified by densitometry using ImageJ. WT and mutant MCT8 expression levels are expressed as MCT8/ GADPH ratio relative to untreated control cells expressing either WT or corresponding mutant MCT8 (100%) and presented as mean 6 SEM of three independent experiments. Statistical significance was tested using one-way analysis of variance followed by Dunnett multiple-comparison test. Statistically significant differences are indicated as follows: *P , 0.05; **P , 0.01. AB, antibody; AU, arbitrary units; EV, empty vector. 5%, respectively). However, in case of the p.delF501 mutant, the proportion of the total amount of p.F501del protein expressed at the cell membrane showed a modest increase after PBA treatment (from ;7% to ;10%), indicating more efficient cell membrane trafficking in the presence of PBA (derived from Fig. 5 ). Together, these findings are in agreement with previous studies (13) and indicate that PBA potentiates the function of WT MCT8 and the p.F501del mutant by increasing MCT8 protein expression levels at the cell membrane. Despite the increase in cell membrane expression levels, the p.R445L mutant showed no functional increase upon treatment with PBA.
Because PBA may act as a chemical chaperone and as a histone deacetylase inhibitor (28), we next explored to what extent an increase in MCT8 mRNA expression levels may underlie the observed increase in MCT8 protein expression levels. Indeed, MCT8 mRNA expression levels increased significantly by approximately threefold in transiently transfected COS-1 cells after incubation with 1 mM PBA compared with untreated control cells and cells exposed to 1% DMSO [ Fig. 6(a) ]. In contrast, mRNA expression levels of GAPDH showed an approximately twofold decrease in the PBA-treated cells, which is in line with previous studies [ Fig. 6(b) ] (29). These findings suggest that at least part of the stimulatory effect of PBA occurs at the transcriptional level for both WT MCT8 and the p.F501del mutant.
Importantly, in both transient and stable overexpression systems, the expression of MCT8 is not controlled by its native promoter. Hence, we aimed to study the efficiency of chaperone treatment in patientderived (p.F501del, p.Q97fsX, or p.R445L) and control fibroblasts. Previous studies have shown that TH uptake is severely impaired in fibroblasts from patients with MCT8 deficiency, suggesting that MCT8 importantly mediates the uptake of TH in these cells (10) . Indeed, T3 uptake capacity Figure 5 . Representative immunoblot analyses on total lysates and the cell surface fraction derived from COS-1 cells transfected with 750 ng pcDNA3 EV, WT, or indicated mutant MCT8. Cells were preincubated in the absence (-) or presence (+) of 1 mM PBA for 48 hours prior to sample preparation. The input sample comprises 5% of the clarified lysate from which the presented surface fraction was derived. MCT8 detection was performed with the N-terminal MCT8 antibody (3353) and visualized with IRDye680 goat anti-rabbit secondary antibody. GAPDH was used as loading control. Note the absence of GAPDH in the cell surface samples, demonstrating the purity of the cell surface fraction. MCT8 and GADPH expression levels were quantified by densitometry using ImageJ. WT and mutant MCT8 expression levels in the input sample (total lysate) are expressed as MCT8/GADPH ratio relative to untreated control cells expressing either WT or corresponding mutant MCT8 (100%), and WT and mutant MCT8 cell surface expression levels are expressed as MCT8 (surface)/GADPH (input) ratio relative to untreated control cells expressing either WT or corresponding mutant MCT8 (100%). All data are presented as mean 6 SEM of two to three independent experiments. Statistical significance was tested using two-way analysis of variance analyses followed by Bonferroni multiple-comparison test. Statistically significant differences are indicated as follows: *P , 0.05; **P , 0.01; ***P , 0.005. of the p.Q97fsX and p.R445L mutant fibroblasts amounted to ;30% of control fibroblasts, whereas T3 uptake by the p.F501del mutant fibroblasts was less affected, amounting to ;50% of control fibroblasts (Fig. 7) . This is in accordance with the relatively mild clinical phenotype of the patient harboring this mutation (9) . To further demonstrate the important contribution of MCT8 to the cellular T3 uptake in human fibroblasts, we next performed T3 uptake assays in the presence or absence of 10 mM silychristin, the most specific MCT8 inhibitor identified to date (30) . T3 uptake by the control and p.F501del patient fibroblasts decreased to similar levels as p.Q97fsX mutant fibroblasts (Fig. 7) .
Finally, the effects of 48-hour preincubation with increasing concentrations of DMSO and PBA on T3 uptake levels in fibroblasts were evaluated. Concentrations of 10 mM PBA and 2% DMSO were generally well tolerated and only resulted in a minor reduction of cellular viability or total protein content [ Fig. 8(a) and 8(b) , middle and right panels]. Preincubation with 2% DMSO significantly increased T3 uptake in control and p.F501del mutant fibroblasts but had no effect on p.Q97fsX and p.R445L mutant fibroblasts [ Fig. 8(a) ]. Preincubation with 10 mM PBA resulted in a small but significant increase in T3 uptake in p.F501del mutant fibroblasts, which was not observed at lower concentrations. No effects were observed in control or p.R445L mutant fibroblasts [ Fig. 8(a)  and 8(b) ]. Unexpectedly, a small and insignificant increase in T3 uptake was also observed in p.Q97fsX mutant fibroblasts after preincubation with 10 mM PBA [ Fig. 8(b) ], which suggests that the observed increase in T3 uptake is not solely the result of the rescue of mutant MCT8 function. Similar results were obtained using NaPB (data not shown). Lower chaperone concentrations did not affect T3 uptake in any of the fibroblast lines [ Fig. 8(a) and 8(b) ]. In contrast to the transient overexpression system, the absolute endogenous MCT8 mRNA expression levels in control or p.F501del mutant fibroblasts did not significantly increase in response to 48-hour incubations with 10 mM PBA [ Fig. 9(a) ]. In agreement with previous studies, mRNA expression levels of the housekeeping gene cyclophilin were found to be reduced by PBA [ Fig. 9(b)] (31) .
Finally, we reasoned that if PBA specifically improves MCT8 mutant function, addition of the MCT8-specific inhibitor silychristin would prevent this increase. We observed that the increase in T3 uptake in p.F501del cells preincubated with 10 mM PBA was not reduced in the presence of 10 mM silychristin during the uptake experiment (Fig. 10) . Indeed, silychristin-sensitive T3 uptake did not differ between cells preincubated without (17% 6 3%) or with (17% 6 4%) 10 mM PBA [ Fig. 9 ; t(6) = 0.10, P = 0.92]. Together, this suggests that the increase in T3 uptake in PBA-treated p.F501del cells is mediated through other T3 transporters than MCT8.
Discussion
MCT8 deficiency results in a severe neurocognitive phenotype, urging the development of an effective treatment. At present, different therapeutic strategies are being explored in a clinical (T3 analogs) and preclinical (gene therapy and chaperone therapy) setting. In the current study, we provide unique insights into the use of chaperones in the treatment of MCT8 deficiency. We here extend and complement previous studies, by demonstrating that the chemical chaperone PBA may also effectively potentiate the function of WT MCT8 and the p.F501del mutant in a transient overexpression model. In addition, we further delineate the underlying molecular mechanism of PBA Figure 6 . WT or p.F501del mutant (a) MCT8 and (b) GADPH mRNA expression levels in COS-1 cells transiently transfected with 100 ng WT or p.F501del mutant MCT8, preincubated in the absence (control) or presence of 1% DMSO or 1 mM PBA for 48 hours (six-well format). The MCT8 primer/probe combination was designed in a way that endogenously expressed csMCT8 could not be detected. Data are presented as means 6 SEM of two independent experiments performed in triplicate and expressed as fold difference compared with untreated COS-1 cells expressing WT MCT8. Statistical significance was tested using two-way analysis of variance analyses followed by Bonferroni multiplecomparison test. Statistically significant differences are indicated as follows: *P , 0.05; ***P , 0.005. action, by demonstrating substantial effects on WT and p.F501del mutant MCT8 mRNA levels in our in vitro overexpression model. Importantly, only minor effects of PBA on cellular T3 uptake were observed in control and patient-derived fibroblasts in which the expression of MCT8 is under the control of its native promoter. Moreover, the effects of PBA in fibroblasts were unchanged in the presence of the MCT8-specific inhibitor silychristin, suggesting that the underlying mechanism is unrelated to the rescue of functional MCT8.
Functional MCT8 is crucial for the maintenance of appropriate intracellular TH levels in different tissues and cell types. In particular, it has a critical role in the transport of TH across the BBB (11). MCT8 deficiency results in a relatively hypothyroid state in cells that highly depend on functional MCT8. Hence, effective therapies should, among others, aim to restore local TH signaling in these cells. In addition to therapeutic approaches using TH analog therapy (32-37) and gene therapy (38) , the use of chemical and pharmacological chaperones has recently been explored in vitro (13, 14) .
The use of chaperone therapy was prompted by the observation that several mutations showed varying impact in different cell types (21, 39) . These observations suggested that some mutations do not (completely) abolish intrinsic transport activity but reduce the abundance of the transporter at the cell membrane by disturbing subcellular trafficking or protein stability in a cell type-dependent way. Based on the beneficial effects observed for chaperone therapy on mutant cystic fibrosis transmembrane conductance regulator (associated with cystic fibrosis) (40) (41) (42) , it was postulated that such mutant proteins may also benefit from chaperone therapy. Indeed, previous studies in stably transfected Madin-Darby canine kidney cells demonstrated that PBA, NaPB, DMSO and, to a lesser extent, genistein increased TH uptake by the p.F501del mutant (13) and several other mutants, most of which were associated with a relatively mild clinical phenotype (14) . In line with these studies, we found that T3 uptake by the p.F501del mutant was stimulated by the chemical chaperone PBA in transiently transfected COS-1 cells. Importantly, we demonstrated that the magnitude of the effect of chaperone therapy is strongly related to the plasmid dose, and thus presumably to the amount of MCT8 protein being synthesized. The strongest effects of PBA were observed at low plasmid concentrations, at which T3 uptake by the p.F501del mutant could be restored to levels observed in untreated WT MCT8-expressing cells. No further gain in T3 transport capacity was observed in cells transfected with higher plasmid levels, suggesting that under these conditions, the maximum transport capacity has already been reached. Hence, the use of relatively high plasmid concentrations may explain the lack of efficacy of chaperone treatment in previous studies using transient overexpression systems (21) .
As expected, neither PBA nor DMSO improved T3 uptake by the Q97fsX mutant, because this mutation prevents the production of full-length MCT8. Although PBA effectively increased the total and surface expression levels of p.R445L mutant protein, no corresponding increase in T3 uptake capacity was observed. This suggests, that the pR445L mutation most likely directly affects the substrate translocation mechanism, which is in line with previous studies demonstrating an important role for Arg445 in substrate interactions (6, 25, 27) .
In contrast to previous studies claiming that PBA increases TH transport by MCT8 mutants but not by WT MCT8, the current study shows similar effect sizes of 1 mM PBA on the T3 uptake function of WT MCT8 and the p.F501del mutant in transiently transfected COS-1 cells. Because WT MCT8 is less susceptible to protein Figure 7 . T3 uptake levels in skin fibroblasts derived from MCT8-deficient patients harboring the indicated MCT8 mutation or two sex-matched control subjects (the average of both control lines is provided) after 30 minutes incubation at 37°C in the absence (-) or presence (+) of 10 mM silychristin (SC). Silychristin is a potent and, thus far the most specific, inhibitor of MCT8-mediated TH transport (30) . Ten micromolars was found to be the lowest SC concentration resulting in maximal MCT8 inhibition, without affecting cell viability (MTT assay) or total protein content (Bradford assay) (data not shown). T3 uptake levels are presented as mean (6 SEM) percentage internalized T3 per milligram protein to correct for differences in cell density between different fibroblast lines (n = 4 to 6). Experiments were performed between P2 and P8, and fibroblasts of the different subjects had the same passage number at time of the experiments. In the absence of silychristin, all three patient-derived fibroblasts lines showed a significantly lower T3 uptake capacity as compared with control cells (P , 0.001; not indicated in the graph). Residual T3 uptake by the p.F501del mutant fibroblasts was significantly higher compared with the p.Q97fsX and p.R445L mutant fibroblasts (P , 0.05; not indicated in the graph), as assessed by repeated-measures two-way analysis of variance with Bonferroni post hoc tests. T3 uptake levels in control and p.F501del mutant fibroblasts were significantly reduced to p.Q97fsX and p.R445L mutant levels in presence of 10 mM silychristin, as assessed by two-way analysis of variance with Bonferroni post hoc tests (*P , 0.05; ***P , 0.005).
misfolding than the p.F501del mutant, the stimulatory effects of PBA cannot be solely attributed to its chaperone function. Although the molecular mechanisms underlying the therapeutic action of PBA are not yet fully understood, they include histone deacetylase inhibition and, consequently, effects on gene expression (28) . Therefore, we here also evaluated the effects of PBA on MCT8 mRNA expression, which has not been addressed Figure 9 . (a) MCT8 and (b) cyclophilin A mRNA expression levels in control (presented as mean of two different control lines) or p.F501del mutant MCT8 fibroblasts, preincubated in the absence (control) or presence of 10 mM PBA for 48 hours. Data are presented as means 6 SEM of two independent experiments in triplicate and expressed as fold difference vs untreated control fibroblasts. Statistical significance was tested using two-way analysis of variance analyses followed by Bonferroni multiple-comparison test. Statistically significant differences are indicated as follows: ***P , 0.005. Figure 8 . T3 uptake levels in patient-derived or control fibroblasts in 30 minutes at 37°C. Cells were preincubated in the absence (control) or presence of (a, left panel) 1% to 2% DMSO or (b, left panel) 1 to 10 mM PBA for 48 hours. In parallel, (a and b, middle panel) cell viability and (a and b, right panel) total protein levels were measured using MTT and Bradford assays, respectively. T3 uptake levels are presented as mean (6 SEM) percentage internalized T3 per milligram protein (n = 4). Statistical significance was tested using two-way analysis of variance analyses followed by Bonferroni multiple-comparison test. Statistically significant differences are indicated as follows: *P , 0.05; **P , 0.01. in previous studies. Indeed, profound stimulatory effects on MCT8 mRNA expression were found, which suggests that at least part of the beneficial effects of PBA occur at the transcriptional level.
Because the expression of MCT8 in stable and transient overexpression systems is under the control of an artificial promoter, it was imperative to also evaluate the effects of PBA in cells in which MCT8 expression is controlled by its native promoter. For this reason, we here evaluated the effects of chaperones on skin fibroblasts, which have been previously shown to be a suitable ex vivo model for MCT8 deficiency (9, 10). Our current studies using the MCT8-specific inhibitor silychristin (30) further underscore the importance of MCT8 for TH transport into fibroblasts and the relevance of this model. Importantly, fibroblasts have been previously used to demonstrate the efficacy of chaperone treatment, including PBA, in other diseases (43) (44) (45) . In contrast to the effects observed in overexpression models, only small, but significant, beneficial effects of high concentrations of PBA were observed in the p.F501del fibroblasts. Although it is intuitive to speculate that an increase in p.F501del mutant function accounts for this observation, the increase in T3 uptake levels observed in PBA-treated fibroblasts was not suppressed by silychristin. In line with this, MCT8 mRNA expression levels did not significantly change upon incubation with PBA, suggesting that PBA also exerts stimulatory effects on other T3 transporters expressed in skin fibroblasts. The exact mechanism underlying this observation and the endogenous transporter(s) involved remain to be elucidated. Thus, the effect of PBA on T3 uptake in fibroblasts does not appear to be specific for WT MCT8 or for the p.F501del mutant.
Regardless of its exact underlying mechanism, the observed increase in T3 uptake in PBA-treated p.F501del fibroblasts might be of clinical significance, because the magnitude of this increase corresponds to the difference in T3 uptake of untreated fibroblasts with the mild p.F501del mutation and cells with the severe p.R445L and p.Q97fsX mutations. As the MCT8-independent response to PBA was less pronounced in the control and p.R445L and p.Q97fsX mutant fibroblasts, the effect of PBA on other transporters than MCT8 may differ per individual. Also, it remains to be elucidated to what extent similar effects can be obtained in other MCT8-dependent cell types, most importantly the endothelial cells of the BBB in which, at least in humans, the redundancy of other TH transporters appears to be limited. Thus, it is yet unclear to what extent the results of the present and previous in vitro studies can be extrapolated to the in vivo situation. Nonetheless, PBA has been shown to cross the BBB and exert effects inside the brain. It should be noted that PBA is also a well-known nitrogen scavenger capable of inducing the urinary excretion of 2 mol of nitrogen per mole of PBA through reaction of its active metabolite phenylacetate with glutamine. Although this mechanism underlies the therapeutic potency of PBA in the treatment of urea cycle defects, it may pose a concern when PBA is applied to patients with a very low body weight and a compromised nitrogen balance due to impaired food intake, as is the case in MCT8 deficiency (46) .
In contrast to previous studies (13, 14) , we did not find any effects of DMSO in transiently transfected COS-1 cells. A potential explanation is that we were unable to apply similar DMSO concentrations in our model due to toxic effects. DMSO was less toxic in fibroblasts, and consequently, higher concentrations could be tested. We found that 2% DMSO potentiated T3 uptake in p.F501del and WT fibroblasts, but not in p.Q97fsX and p.R445L fibroblasts. Because DMSO cannot be applied in clinical practice, we did not further follow-up on this finding.
In general, the magnitude of the effect of chaperone treatment may depend on (1) the underlying pathogenic mechanism of the mutation and (2) the cell model, but most likely also on (3) cell type-specific factors. Because chaperones such as PBA may also affect mRNA expression, the effects of such compounds should be preferably studied in the native genomic context. Although easily accessible, the role of MCT8 in skin Figure 10 . T3 uptake levels in patient-derived or control fibroblasts in 30 minutes at 37°C in the absence (-) or presence of 10 mM silychristin (SC) after preincubation in the absence (control) or presence of 10 mM PBA for 48 hours. T3 uptake levels are presented as mean (6 SEM) percentage internalized T3 per milligram protein (n = 4). Please note that preincubation of the p.F501del mutant fibroblasts with 10 mM PBA resulted in a significant increase in intracellular T3 accumulation as compared with untreated cells. However, at least part of this gain in T3 uptake function was not sensitive to silychristin, because a significant difference was observed between both conditions once silychristin was added during the uptake experiment (horizontal bar). Statistical significance was tested using two-way analysis of variance analyses followed by Bonferroni multiple-comparison test. Statistically significant effects of PBA are indicated as follows: # P , 0.05. Statistically significant effects of silychristin are indicated as follows: *P , 0.05; ***P , 0.005.
fibroblasts is yet unclear but appears to be of less physiological relevance compared with its role in the BBB and in neuronal cells. Therefore, it would be highly interesting to study the impact of chaperone treatment in disease models representing these cell types.
Taken together, we here demonstrate that PBA effectively potentiates T3 uptake by WT MCT8 and the p.F501del mutant in transiently transfected COS-1 cells. In contrast, only minor effects were observed in p.F501del fibroblasts. The latter effects seem MCT8 independent and are likely mediated through other transporters. Because the magnitude of the effect of chaperone therapy strongly depends on the disease model, more extensive preclinical studies are warranted before clinically available chaperones should be considered as a treatment option in patients with MCT8 deficiency.
